-
Signature
-
Sean D. Mersten, Attorney in Fact for Mark E. Delaney
-
Stock symbol
-
DGX
-
Transactions as of
-
Nov 18, 2025
-
Transactions value $
-
-$1,488,683
-
Form type
-
4
-
Date filed
-
11/20/2025, 04:28 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| DELANEY MARK E |
SVP & Chief Commercial Officer |
500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS |
Sean D. Mersten, Attorney in Fact for Mark E. Delaney |
2025-11-20 |
0001955265 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
DGX |
Common Stock |
Options Exercise |
$1.13M |
+7.85K |
+104.2% |
$144.47 |
15.4K |
Nov 18, 2025 |
Direct |
F1 |
| transaction |
DGX |
Common Stock |
Options Exercise |
$14.3K |
+100 |
+0.65% |
$143.33 |
15.5K |
Nov 18, 2025 |
Direct |
F1 |
| transaction |
DGX |
Common Stock |
Sale |
-$1.49M |
-7.95K |
-51.34% |
$187.35 |
7.53K |
Nov 18, 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
DGX |
Non-Qualifed Stock Option (right to buy) |
Options Exercise |
-$1.13M |
-7.85K |
-100% |
$144.47 |
0 |
Nov 18, 2025 |
Common Stock |
7.85K |
$144.47 |
Direct |
F1, F2 |
| transaction |
DGX |
Non-Qualifed Stock Option (right to buy) |
Options Exercise |
-$14.3K |
-100 |
-1.32% |
$143.33 |
7.48K |
Nov 18, 2025 |
Common Stock |
100 |
$143.33 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: